This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

After a positive FDA panel for Aimmune's and FDA decision looming, we will discuss the commercial potential of Palforzia. NOTE: Call will have a proprietary survey, run by SI, of high volume pediatric allergists/immunologists available.

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr Robert Wood - MD

Institution: Johns Hopkins University

  • Professor of Pediatrics and Chief of Pediatric Allergy and Immunology at the Johns Hopkins University School of Medicine, Director of the Johns Hopkins Pediatric Clinical Research  Unit, and Professor of International Health at the Johns Hopkins Bloomberg School of Public Health.  
  • Currently treats over 1,000 patients with peanut allergy.
  • Research focuses on novel treatment approaches for both food allergy and asthma, for which he is currently principal investigator for over 20 ongoing studies.

Interview Questions

Questions to come from STAT Reporters!

Added By: joe_mccann

As a bonus, SEA subscribers will get access to a proprietary survey run by Slingshot Insights on the commercial potential of peanut allergy therapies. Respondents will be pediatric immunologists, and allergists, with a large number of peanut allergy patients.

Added By: joe_mccann

The first day of therapy AIMT calls the IDE, Initial Dose Escalation, involving 5 consecutive updoses. Can Dr. Woods please comment on the necessity of this and the logistics?

Added By: trip

Are You Interested In These Questions?

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.